<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><description>It takes nothing to join the crowd, but it takes everything to stand alone</description><managingEditor> (hellodword)</managingEditor><pubDate>Sat, 22 May 2021 07:27:49 +0800</pubDate><image><url>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</url><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>ADCs药物申报IND/NDA的药学审评要点</title><link>https://mp.weixin.qq.com/s/kDNk56gnyrl1PUgBFGkLyg</link><description></description><content:encoded><![CDATA[ADCs药物申报IND/NDA的药学审评要点]]></content:encoded><pubDate>Fri, 21 May 2021 19:14:14 +0800</pubDate></item><item><title>中美欧——变更对比（CDE首席科学家解读PACMP）</title><link>https://mp.weixin.qq.com/s/OTE4ZG56aEYxxQyC-QXIGg</link><description></description><content:encoded><![CDATA[中美欧——变更对比（CDE首席科学家解读PACMP）]]></content:encoded><pubDate>Fri, 21 May 2021 19:14:14 +0800</pubDate></item><item><title>超滤在生物医药领域的应用</title><link>https://mp.weixin.qq.com/s/ehhYX5Aexao063Mb3_RpnQ</link><description></description><content:encoded><![CDATA[超滤在生物医药领域的应用]]></content:encoded><pubDate>Fri, 21 May 2021 19:14:14 +0800</pubDate></item><item><title>FDA药物稳定性试验指导原则中文版</title><link>https://mp.weixin.qq.com/s/Bnac6FHtjO4JjUMZLe5DXQ</link><description></description><content:encoded><![CDATA[FDA药物稳定性试验指导原则中文版]]></content:encoded><pubDate>Fri, 21 May 2021 19:14:14 +0800</pubDate></item><item><title>药物研究中制剂有关物质研究的重点及策略</title><link>https://mp.weixin.qq.com/s/ziWgdUUtVeHSpVuRqb5aqA</link><description></description><content:encoded><![CDATA[药物研究中制剂有关物质研究的重点及策略]]></content:encoded><pubDate>Fri, 21 May 2021 19:14:14 +0800</pubDate></item><item><title>仿制药研发流程-质量研究详细讲解</title><link>https://mp.weixin.qq.com/s/pjJFNr-zwOtdXFrsqg-w8g</link><description></description><content:encoded><![CDATA[仿制药研发流程-质量研究详细讲解]]></content:encoded><pubDate>Fri, 21 May 2021 19:14:14 +0800</pubDate></item><item><title>基于FDA 工艺验证指南&amp;PDA TR60的全生命周期工艺验证</title><link>https://mp.weixin.qq.com/s/85Cv6RZm82Rx6KvvZkLAtw</link><description></description><content:encoded><![CDATA[基于FDA 工艺验证指南&PDA TR60的全生命周期工艺验证]]></content:encoded><pubDate>Thu, 20 May 2021 19:28:57 +0800</pubDate></item><item><title>新冠疫苗2.0将会上市，效果惊人！要等出新一代疫苗再打吗？</title><link>https://mp.weixin.qq.com/s/RaYWcYHn6biHY_-WMQc3qg</link><description></description><content:encoded><![CDATA[新冠疫苗2.0将会上市，效果惊人！要等出新一代疫苗再打吗？]]></content:encoded><pubDate>Thu, 20 May 2021 19:28:57 +0800</pubDate></item><item><title>得了癌症怎么治？2021年最新肿瘤治疗方案汇总</title><link>https://mp.weixin.qq.com/s/Im3OrVi5Qv-snMaMGTVrAQ</link><description></description><content:encoded><![CDATA[得了癌症怎么治？2021年最新肿瘤治疗方案汇总]]></content:encoded><pubDate>Thu, 20 May 2021 19:28:57 +0800</pubDate></item><item><title>陕西 | 药品上市后变更备案管理工作细则（征求意见稿）</title><link>https://mp.weixin.qq.com/s/9Nb14HCzsL4N-UmxS5Xrsg</link><description></description><content:encoded><![CDATA[陕西 | 药品上市后变更备案管理工作细则（征求意见稿）]]></content:encoded><pubDate>Thu, 20 May 2021 19:28:57 +0800</pubDate></item><item><title>图解｜《药物警戒质量管理规范》</title><link>https://mp.weixin.qq.com/s/UPGASznuPLPZ430FLYUm8Q</link><description></description><content:encoded><![CDATA[图解｜《药物警戒质量管理规范》]]></content:encoded><pubDate>Thu, 20 May 2021 19:28:57 +0800</pubDate></item><item><title>关于阿达木单抗生物类似药质量相似性评价要点的初步探讨</title><link>https://mp.weixin.qq.com/s/Jlctvcw42GzwdFUim_L1jQ</link><description></description><content:encoded><![CDATA[关于阿达木单抗生物类似药质量相似性评价要点的初步探讨]]></content:encoded><pubDate>Wed, 19 May 2021 20:36:40 +0800</pubDate></item><item><title>CDE答疑：生物制品上市后变更专题</title><link>https://mp.weixin.qq.com/s/MWe28VmOle6pm1TYq02oSQ</link><description></description><content:encoded><![CDATA[CDE答疑：生物制品上市后变更专题]]></content:encoded><pubDate>Wed, 19 May 2021 20:36:40 +0800</pubDate></item><item><title>无菌生产工艺控制的五点关注</title><link>https://mp.weixin.qq.com/s/MwYzlLszN5hD2RgSL28Y5Q</link><description></description><content:encoded><![CDATA[无菌生产工艺控制的五点关注]]></content:encoded><pubDate>Wed, 19 May 2021 20:36:40 +0800</pubDate></item><item><title>复习——生物制品上市申请药学申报资料常见问题和审评关注要点分析</title><link>https://mp.weixin.qq.com/s/8ziv-3h7MYQNfs1D0klE0g</link><description></description><content:encoded><![CDATA[复习——生物制品上市申请药学申报资料常见问题和审评关注要点分析]]></content:encoded><pubDate>Tue, 18 May 2021 20:34:37 +0800</pubDate></item><item><title>MAH制度红利持续释放，引燃研发创新项目交易之火</title><link>https://mp.weixin.qq.com/s/vqkq0AiiSFlvj1n1r1GIMg</link><description></description><content:encoded><![CDATA[MAH制度红利持续释放，引燃研发创新项目交易之火]]></content:encoded><pubDate>Tue, 18 May 2021 20:34:37 +0800</pubDate></item><item><title>CAR-T在实体瘤的治疗中最大的阻碍之一：肿瘤微环境</title><link>https://mp.weixin.qq.com/s/z-v-3XmLu_muFKfiU_rjGQ</link><description></description><content:encoded><![CDATA[CAR-T在实体瘤的治疗中最大的阻碍之一：肿瘤微环境]]></content:encoded><pubDate>Tue, 18 May 2021 20:34:37 +0800</pubDate></item><item><title>学习笔记《溶瘤病毒类药物临床试验设计指导原则（试行）》</title><link>https://mp.weixin.qq.com/s/ugyt5B5STA3fp3HbkFfnaw</link><description></description><content:encoded><![CDATA[学习笔记《溶瘤病毒类药物临床试验设计指导原则（试行）》]]></content:encoded><pubDate>Tue, 18 May 2021 20:34:37 +0800</pubDate></item><item><title>CDE-CTD共性问题汇总及解答</title><link>https://mp.weixin.qq.com/s/WjMfPd0bpujLp98eGqTG1Q</link><description></description><content:encoded><![CDATA[CDE-CTD共性问题汇总及解答]]></content:encoded><pubDate>Mon, 17 May 2021 19:41:59 +0800</pubDate></item><item><title>NGM Biopharma技术全梳理</title><link>https://mp.weixin.qq.com/s/MfQQ22N8R7DvBKD5IWY_ag</link><description></description><content:encoded><![CDATA[NGM Biopharma技术全梳理]]></content:encoded><pubDate>Mon, 17 May 2021 19:41:59 +0800</pubDate></item></channel></rss>